monitoring devices for home use, a term that makes a distinction between the two types of monitoring is needed. The term PCGM will be used in this article.
Professional continuous glucose monitoring involves continuous glucose monitoring typically for a 3-5 day period with the patient being unaware of the result until the stored data are transferred to a data management system and analyzed. The patient is required to do routine SMBG and to record dietary intake and activity during the test period. The test is ideally done on days that are representative of "typical" days.
The goal of PCGM is to correlate the influences of diet, glucose-lowering medications, events, and physical activity on glucoses during an entire 24-72 h period on glucose control. The advantage of the test over "real-time" continuous glucose monitoring is that the patient's behavior is not influenced by the continuous feedback of glucose results. Therefore, the unbiased results can be used to make conclusions concerning various factors influencing the patient's diabetes control and therapeutic treatment recommendations, including changes in diet, activity, and medication, can be made ( Table 1) . The PCGM test is easier to use by the patient than the "real-time" or "personal" continuous glucose monitor (CGM) and requires minimal training and setup time. Another advantage is insurance reimbursement for PCGM (this has not been specifically defined up to this point), which is available to many more patients than for real-time or personal CGM. Professional continuous glucose monitoring has similarities to other aspects of retrospective monitoring in medicine and has been called the "Holter monitor of diabetes." Retrospective monitoring has been used for decades in cardiology.
The first PCGM device was the Minimed CGMS Physician-Use Glucose Monitoring System approved by the Food and Drug Administration in 1999. In 2003, the CGMS ® System Gold™ was introduced by Medtronic Minimed. This device required data entry in a recorder that was attached to the subcutaneous sensor by a cable and could be downloaded after use. In 2008, the iPro was introduced and is the model currently in use. Dexcom, in 2009, developed a software adaption in the Dexcom 7, which allows it to be used for retrospective glucose monitoring.
Continuous glucose monitor technology utilizes a glucose sensor placed into the subcutaneous space, which measures the interstitial glucose continuously. The sensor consists of two semipermeable membranes that surround an impregnated glucose-oxidase-enzymecontaining material. When glucose and oxygen pass through the semipermeable membrane and react with the glucose oxidase enzyme in the presence of glucose, hydrogen peroxide is generated with two hydrogen ions, producing an electronic signal. The "signal" is then recorded and interpreted as glucose proportional to the level of glucose present in the interstitial fluid. Current sensor software stores and delivers a glucose result every 5 min (Figure 1) .
The CGM sensor measures glucose in the interstitial space while glucose meters measure glucose from blood vessels (mixed capillaries) (Figure 2 ). Because these two testing areas are physically separate, the glucose takes time to travel from one place to the other. When glucose levels are stable, such as in the fasting state, the glucose levels are usually nearly identical in the interstitial and capillary spaces. However, when glucose levels are rapidly changing, such as after a meal, the sensor glucose may lag behind metered glucose due to the time needed for glucose to travel from capillary to interstitial space. This delay can be up to approximately 20 min due to physiological delay and technology delay (filters and storage of data every 5 min). This delay has been called the "lead-lag phenomena." Currently, SMBG is the reference for glucose levels, so the CGM sensor needs to be calibrated using a meter blood glucose value as the reference.
A number of studies have supported the utility and clinical benefit of using PCGM. One study by Boland and colleagues 1 used PCGM in pediatric patients with a mean HbA1c of 7.7% who were considered to have adequately controlled fasting glucoses. Professional continuous glucose monitoring demonstrated over 90% of patients had postprandial hyperglycemia, with almost half reaching levels over 300 mg/dl. Almost 70% of the 2. Professional continuous glucose monitoring is easier for the patient to use than the real-time monitor and requires minimal training and setup time.
3. Insurance reimbursement for PCGM is available to many more patients than for real-time glucose monitoring.
CGMs revealed frequent and prolonged asymptomatic hypoglycemia (glucose <60 mg/dl). It was concluded that "repeated use of the CGMS [continuous glucose monitoring system] may provide a means to optimize basal and bolus insulin replacement in patients with type 1 diabetes." Clearly, uncovering hyperglycemia and hypoglycemia with PCGM is relevant to improvement in diabetes management.
Another study by Tanenberg and associates 2 evaluated insulin-treated patients with diabetes, ranging in age from 18-76 years, who were assigned to insulin therapy adjustments based on either CGM or SMBG values (51 in the CGM group and 58 in the SMBG group). There were no differences in HbA1c levels between the CGM group and the SMBG group at baseline (9.1% ± 1.1% versus 9.0% ± 1.0%, p = .70). Both groups showed statistically Sensor signal significant (p < .001) and similar (p = .95) improvement in HbA1c levels after 12 weeks of study. However, the CGM group had a significantly shorter duration of hypoglycemia (sensor glucose ≤60 mg/dl) at week 12 of the study (49.4 ± 40.8 versus 81.0 ± 61.1 min/event, p = .009). This finding led to the conclusion that "use of the CGMS [continuous glucose monitoring system] to guide therapy adjustments in patients with insulintreated diabetes reduces the duration of hypoglycemia compared with therapy adjustments guided by SMBG values alone."
A pediatric population was studied by Kaufman and coworkers 3 using PCGM. This study contained a total of 47 patients with a mean HbA1c value of 8.6 ± 1.6% (mean age 11.8 ± 4.6 years, youngest 2.7 years, and diabetes duration 5.5 ± 3.5 years) on three to four insulin injections per day (n = 24) or insulin pump therapy (n = 23). The patients were followed with the CGM for a mean of 69.5 ± 28 h. Comparisons were made between the number of high (>150 mg/dl) and low (<70 mg/dl) glucose patterns discerned with the sensor or the logbook. In addition, HbA1c levels were evaluated. In patients on injection therapy, 30 high or low glucose patterns were identified with the logbook records and 120 patterns with the CGM. Specific alterations of the diabetes regimen were made. An overall significant change in HbA1c, from three months before wearing the sensor to six months after (analysis of variance 0.04), was found in the subjects. Post hoc analysis showed a significant change in HbA1c from 8.6 ± 1.5% at baseline to 8.4 ± 1.3% at three months. The authors concluded that "the CGMS [continuous glucose monitoring system] can be used by pediatric patients to detect abnormal patterns of glycemia. The information that was obtained could be used to alter the diabetes regimen and impact glycemic outcome." 3 The PCGM test has been evaluated in diabetes and pregnancy. Murphy and colleagues 4 studied 71 pregnant women, 16-45 years of age, with type 1 or type 2 diabetes. Standard prenatal care with SMBG was compared with prenatal care using PCGM. Continuous monitoring for up to 7 days, at intervals of 4-6 weeks between 8 and 32 weeks of gestation, was used to make therapeutic changes at intervals of 4-6 weeks. Use of PCGM during pregnancy was associated with improved glycemic control (lower HbA1c) in the third trimester (26-32 weeks), decreased birth weight scores, and reduced risk of macrosomia. There were no differences between groups in overall pregnancy outcomes.
Other studies have shown improved HbA1c, 5 greater detection of hypoglycemia, 6 and improved detection of severe hypoglycemia 7 with use of PCGM.
Indications for the PCGM include ( Table 2) recurrent hypoglycemia, hypoglycemic unawareness, pregnancy, and HbA1c over target. Professional continuous glucose monitoring may be useful when discrepancies exist between SMBG and the HbA1c. The iPro components include the glucose sensor that is inserted into the subcutaneous tissue, the recorder that attaches to the sensor to record the information, and the insertion device used to insert the glucose sensor (Figure 3) . In addition, a charger is provided to charge the recorder and a "wand" is used to start communication between the iPro and the software. Lastly, there is a "tester" to test the iPro and facilitate downloading of the recorder. Software called Solutions is downloaded to a personal computer, and the iPro is downloaded wirelessly to the personal computer with a wireless link called ComLink. The only disposable component is the sensor. The other parts are reusable.
Once the data are downloaded via the wireless link, there are five available reports that can be customized. The reports include a sensor summary, sensor modal day, sensor modal time, sensor daily detail, and the patient log sheet. It should be emphasized that the patient log sheet, in which SMBG results, activities, and diet are recorded, is essential to interpreting the test results
The sensor summary report (Figure 4 ) provides the following three types of information:
1. Sensor information. The number of readings that are generated each day. A full day of sensor usage provides 288 readings. The first and last days of the test are usually not full days, so half or less of the usual number of readings will be available. The data are less than optimal if the patient uses the sensor less than 50% of the time. Sensor information also includes the average and ranges of the sensor and glucose meter glucose readings and standard deviation (SD). Standard deviation indicates how variable sensor readings are. Patients who do not have diabetes may have a SD around 20, while someone with suboptimal diabetes control may have a SD of 60 or even more.
2. Optimal accuracy. Ideally sensors and meter readings should be identical. Realistically, this is impossible due to the reasons discussed earlier-measuring fluid in two different dynamic spaces. The sensor is automatically calibrated based on the meter readings, which should ideally be done by the patient four times each day of the test. The optimal accuracy part of the report is essentially a report on the quality of the test. It shows the number of paired readings, that is, the number of times that the meter readings were "paired" with the sensor readings, ≥3 is ideal. Less than this number per day may be associated with a less reliable result. A very important part of the optimal accuracy is the mean absolute difference (MAD). The MAD is the average difference between sensor and meter readings expressed as a percentage. Values of <28% are considered optimal. If the patient has a narrow glucose range (<100 mg/dl), then a value of <18% would be optimal.
3. Glucose excursion shows glucose ranges and displays the percentage of glucoses above, below, and at target in a color-coded pie chart format.
The next report is the sensor modal day. The sensor modal day overlays sensor readings of each day into one 24 h graph so that patterns of glucose on multiple days can be evaluated.
The sensor modal time report breaks the monitored days into time blocks that are programmed by the user. The software allows for setting times for meals and three other time blocks. The first time block is before and after breakfast, typically from 6-10 am; the second is lunch, typically from 11 am until 3 pm; and the third is supper at 5-8 pm. Time block A is commonly set to the overnight period, for example, 11 pm until 6 am; block B might be set for the dawn effect period; and block C is commonly set for the entire 24 h period.
The next report is the sensor daily detail, which separates each day individually and displays the days side by side so that the relationship of one day to another can be evaluated. For example, the glucose results from 12-6 am can be related to the glucoses and events of the evening before. Event markers can be superimposed on the daily detail report to denote mealtimes and times when insulin is administered. Event markers can be entered by the patient in the One Touch Ultra glucose monitor and can then be downloaded directly to the software to be shown on the reports or can be manually entered when the logbook is reviewed at the time of the download.
Though not a classic report, the logbook is a critical part of the analysis of data since it contains information about diet and day-to-day occurrences such as exercise and activity. The logbook also details when and how much glucose-lowering medication is taken.
A concise and comprehensive approach to interpreting the CGM includes evaluating the sensory summary report and the sensor modal day and correlating the results to the logbook information. The following is a suggested approach to interpretation and reporting of results: The PCGM report template, including the above information, could be used in an electronic medical record, and a template can be used to formalize and standardize the report ( Table 3) .
Two patient examples are detailed in Appendix 1, which includes the patient history, the PCGM results, and the interpretation with recommendations.
General advice about reporting includes the following:
1. In the absence of a pattern, focus on events and occurrences and their effect on glucoses. 2. Aim to find 2-3 areas of improvement or "vignettes" and 2-3 recommendations or changes. Organizing the use of CGMs in a medical office requires a number of elements. An initial purchase of equipment and designated personnel in the medical office trained in the initiation and downloading of the CGMs are needed.
(The PCGM equipment and software are owned by the medical office.) Having a process in place for initiation, downloading, and interpreting the results is essential.
The ideal process might include the following:
1. Order the CGM at the time of the office visit.
2. Initiate the CGM after the office visit on the same day.
3. Schedule the patient for another appointment in 3-4 days to have the sensor downloaded to review and discuss the result and make appropriate treatment changes.
Potential challenges to the use of the retrospective CGM include reimbursement issues and inconvenience for the patient. The current sensor is lightweight and unobtrusive and is water resistant. The patient can shower with the sensor in place. The old version, the CGMS Gold, was bulky and required entry of event markers by the patient. The iPro requires almost no attention. Occasionally, a patient may have skin hypersensitivity to the sensor adhesive. The American Medical Association has created two CPT codes that can be used for Professional CGM procedures:
CPT code 95250 covers all services relating to PCGM startup (i.e., sensor insertion, hookup of iPro recorder, patient training), sensor removal, and data download.
• The national average Medicare reimbursement for 95250 is $128 if billed under a physician provider number. a Private payors generally pay more for this code.
• Continuous glucose monitoring services performed by any qualified staff member (e.g., registered nurses, medical assistants, lab technicians, registered dietitians) under the supervision of the physician or midlevel practitioner can be billed under 95250 using the provider number of the physician, midlevel practitioner, or hospital. Payment may be lower if billed under a midlevel practitioner provider (typically 15% lower).
CPT code 95251 is specific to the service of interpreting CGM data from the PCGM evaluation. CPT code 95250 is used when the CGM is downloaded (Figure 5) . CPT code 95251 can be used to bill for interpreting the report. If 95250 and 95251 are used with evaluation and management services done on the same day, then the modifier "-25" should be added. CPT code 95251 does not require face-to-face interaction and can be billed as separate from the patient encounter. year, and the unit will likely have to be replaced yearly.
The Dexcom 7+ can also be used for retrospective continuous glucose monitoring by calling the Dexcom tech support department and obtaining a code that is entered into the Dexcom 7+ receiver to "blind" the device.
In conclusion, PCGM is a valuable tool in the evaluation of diabetes control by detecting episodes of hypoglycemia and hyperglycemia. The PCGM test requires very little patient interaction, and it offers a relatively unbiased assessment of 3-5 days of diabetes control. The use of real-time CGM is on the rise. However, reimbursement issues and patient acceptance limit its use. Reimbursement is available to many more patients with type 1 and type 2 diabetes for PCGM than real-time CGM. In addition, PCGM can be used as an introduction to continuous monitoring for patients with diabetes and may help patients understand the utility of continuous monitoring. 
